Kenneth J. Pienta

Kenneth J. Pienta's AcademicInfluence.com Rankings

Kenneth J. Pienta

Medical

#416

World Rank

#575

Historical Rank

#171

USA Rank

Oncology

#17

World Rank

#18

Historical Rank

USA Rank

medical Degrees

Kenneth J. Pienta

Law

#1449

World Rank

#1826

Historical Rank

#739

USA Rank

Common Law

#31

World Rank

#34

Historical Rank

USA Rank

law Degrees

Download Badge

Medical
Law

Why Is Kenneth J. Pienta Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Kenneth J. Pienta is a medical doctor and the Donald S. Coffey professor of urology and professor of oncology and pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. He also serves as the director of research at the Brady Urological Institute.

(See a Problem?)

Kenneth J. Pienta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. (2006) (2694)
The polycomb group protein EZH2 is involved in progression of prostate cancer (2002) (2596)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer (2012) (2144)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer (2008) (1744)
Delineation of prognostic biomarkers in prostate cancer (2001) (1733)
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer (2005) (1539)
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. (2002) (1038)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer (2013) (915)
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (2007) (854)
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. (2005) (784)
Integrative molecular concept modeling of prostate cancer progression (2007) (725)
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. (2011) (706)
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression (2010) (689)
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. (2011) (650)
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. (2007) (646)
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition (2008) (636)
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases (2004) (627)
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing (2013) (617)
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study (2011) (612)
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex (2013) (606)
Identification of targetable FGFR gene fusions in diverse cancers. (2013) (606)
Autoantibody signatures in prostate cancer. (2005) (606)
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. (1997) (599)
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. (2002) (597)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. (2009) (579)
Targeting the tumour stroma to improve cancer therapy (2018) (574)
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. (2006) (539)
Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters (2016) (519)
CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* (2009) (501)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (2020) (494)
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer* (2008) (483)
Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo (2003) (473)
Testicular cancer. (2004) (463)
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer (2006) (427)
Galectin-3 induces endothelial cell morphogenesis and angiogenesis. (2000) (427)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. (2017) (407)
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. (2011) (398)
Skeletal Localization and Neutralization of the SDF‐1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo (2004) (391)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
Evolution of cooperation among tumor cells (2006) (381)
The Current State of Hormonal Therapy for Prostate Cancer (2002) (375)
Classification of current anticancer immunotherapies (2014) (357)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. (2017) (354)
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. (2007) (346)
The role of the nuclear matrix in the organization and function of DNA. (1986) (332)
Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis (2002) (331)
Recruitment of Mesenchymal Stem Cells Into Prostate Tumors Promotes Metastasis (2013) (329)
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. (2007) (322)
Stability of the hybrid epithelial/mesenchymal phenotype (2016) (319)
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer (2007) (319)
Risk Factors for Prostate Cancer (1993) (317)
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. (2000) (304)
VCaP, a cell-based model system of human prostate cancer. (2001) (304)
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses (2007) (301)
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. (2009) (296)
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. (2003) (281)
Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment (2009) (279)
Global gene expression profiling of circulating tumor cells. (2005) (279)
Classifying the evolutionary and ecological features of neoplasms (2017) (276)
GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. (2010) (273)
Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. (2014) (271)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer (2013) (269)
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. (1995) (264)
Cancer as a disease of DNA organization and dynamic cell structure. (1989) (262)
Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. (2000) (249)
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. (2006) (245)
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. (2010) (245)
Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. (1998) (244)
The biology and treatment of oligometastatic cancer (2015) (230)
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. (2007) (226)
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. (1998) (220)
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. (2007) (219)
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. (2010) (218)
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. (1994) (217)
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. (2009) (215)
Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer (2008) (213)
A Structural Analysis of the Role of the Nuclear Matrix and DNA Loops in the Organization of the Nucleus and Chromosome (1984) (211)
Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer (2013) (208)
Bone turnover mediates preferential localization of prostate cancer in the skeleton. (2005) (207)
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging (2017) (207)
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. (1999) (204)
The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites (2008) (202)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone (2004) (200)
Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations (2017) (200)
Stromal factors involved in prostate carcinoma metastasis to bone (2003) (198)
Cancer stem cells and their role in metastasis. (2013) (195)
The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. (2009) (192)
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa (2008) (189)
The Role of αvβ3 in Prostate Cancer Progression (2002) (188)
Couples' experiences with prostate cancer: focus group research. (2002) (184)
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. (2001) (183)
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. (1998) (181)
Identification of nuclear matrix proteins in the cancer and normal rat prostate. (1991) (175)
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. (2011) (175)
Advances in Prostate Cancer Chemotherapy: A New Era Begins 1 (2005) (174)
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. (2008) (173)
Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. (2005) (172)
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment (2019) (172)
The role of alpha(v)beta(3) in prostate cancer progression. (2002) (170)
Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia (2013) (166)
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation (2016) (165)
CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation* (2008) (165)
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. (1999) (165)
MIM, a potential metastasis suppressor gene in bladder cancer. (2002) (162)
Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. (1993) (161)
Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer (2004) (159)
Nuclear structure and the three‐dimensional organization of DNA (1991) (159)
Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests (2017) (157)
Calcitic microlenses as part of the photoreceptor system in brittlestars (154)
Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. (2008) (153)
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. (2009) (152)
A glycolytic mechanism regulating an angiogenic switch in prostate cancer. (2007) (151)
The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy (2007) (151)
Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. (2001) (150)
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. (1996) (149)
Erythropoietin Couples Hematopoiesis with Bone Formation (2010) (147)
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells (2013) (147)
The tissue matrix: cell dynamics and hormone action. (1990) (146)
Therapeutic Targeting of SPINK1-Positive Prostate Cancer (2011) (146)
Coupling the modules of EMT and stemness: A tunable ‘stemness window’ model (2015) (145)
Mechanisms of cancer cell metastasis to the bone: a multistep process. (2011) (144)
Dickkopf‐1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis (2008) (144)
The evolving biology and treatment of prostate cancer. (2007) (144)
Apoptosis of circulating tumor cells in prostate cancer patients (2004) (143)
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. (2005) (143)
Axl as a mediator of cellular growth and survival (2014) (142)
Expression and activation of αvβ3 integrins by SDF‐1/CXC12 increases the aggressiveness of prostate cancer cells (2007) (141)
Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. (1999) (141)
APC/CTNNB1 (β‐catenin) pathway alterations in human prostate cancers (2002) (141)
Correlation of nuclear morphometry with progression of breast cancer (1991) (139)
Integrative analysis of genomic aberrations associated with prostate cancer progression. (2007) (139)
The current state of preclinical prostate cancer animal models (2008) (136)
Cell structure and DNA organization. (1991) (134)
Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells (2014) (134)
Polarization of Prostate Cancer-associated Macrophages Is Induced by Milk Fat Globule-EGF Factor 8 (MFG-E8)-mediated Efferocytosis* (2014) (131)
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking (2009) (129)
Tumor-associated angiogenesis in prostate cancer. (1993) (128)
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. (2012) (126)
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges (2016) (123)
384 hanging drop arrays give excellent Z‐factors and allow versatile formation of co‐culture spheroids (2012) (122)
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. (2000) (121)
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors (2004) (121)
CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER (2008) (120)
Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. (1995) (119)
Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. (2005) (117)
Decreased galectin‐3 expression in prostate cancer (2000) (116)
GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation (2013) (113)
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets (2013) (111)
Regulation of prostate cancer progression by galectin-3. (2009) (110)
OVOL guides the epithelial-hybrid-mesenchymal transition (2015) (107)
Modeling Somatic Evolution in Tumorigenesis (2006) (106)
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. (2007) (106)
Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0 (2017) (105)
Dynamic process of prostate cancer metastasis to bone (2004) (104)
Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis (2019) (102)
Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance (2019) (101)
Simulating the Hallmarks of Cancer (2006) (100)
DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis1 (2016) (100)
Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. (1994) (98)
Single cell trapping in larger microwells capable of supporting cell spreading and proliferation (2010) (97)
Nuclear‐Cytoskeletal interactions: Evidence for physical connections between the nucleus and cell periphery and their alteration by transformation (1992) (97)
Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. (2007) (97)
Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. (2007) (97)
Nuclear matrix proteins in normal and breast cancer cells. (1993) (97)
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. (2002) (97)
TBK1 regulates prostate cancer dormancy through mTOR inhibition. (2013) (96)
Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates (2012) (96)
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. (1997) (95)
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. (2005) (95)
Tumor expressed PTHrP facilitates prostate cancer‐induced osteoblastic lesions (2008) (95)
Cooperation among cancer cells: applying game theory to cancer (2018) (92)
The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. (2003) (92)
The Cancer Diaspora: Metastasis beyond the Seed and Soil Hypothesis (2013) (92)
Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. (2010) (92)
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. (2011) (91)
Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. (2000) (91)
Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer (2012) (90)
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) (2021) (89)
Galectin-3 is a nuclear matrix protein which binds RNA. (1995) (88)
ETS rearrangements and prostate cancer initiation (2009) (87)
PAR1‐mediated NFκB activation promotes survival of prostate cancer cells through a Bcl‐xL‐dependent mechanism (2005) (87)
FYN is overexpressed in human prostate cancer (2009) (86)
Metastatic prostate cancer remains incurable, why? (2018) (86)
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) (2017) (84)
An in vivo mouse model for human prostate cancer metastasis. (2008) (84)
Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear Matrix (1993) (82)
Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone (2017) (82)
TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. (2017) (82)
Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. (2012) (82)
Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. (2010) (81)
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. (2017) (81)
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. (2002) (80)
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium (2012) (80)
Revisiting Seed and Soil: Examining the Primary Tumor and Cancer Cell Foraging in Metastasis (2017) (79)
Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies (2018) (79)
CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12 (2008) (79)
An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. (1994) (78)
Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for Bone Metastatic Tumors (2011) (78)
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. (2006) (78)
Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples (2016) (78)
Hormone Resistance in Prostate Cancer (1998) (76)
Technical challenges in the isolation and analysis of circulating tumor cells (2016) (76)
The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. (1991) (76)
IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation (2012) (75)
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis (2006) (75)
Cancer as a complex adaptive system. (1996) (75)
Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. (1998) (75)
In Vivo Visualization of Metastatic Prostate Cancer and Quantitation of Disease Progression in Immunocompromised Mice (2003) (75)
Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients (2011) (74)
Prostate Specific Membrane Antigen Targeted 18F‐DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study (2018) (74)
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. (2002) (73)
Ecology meets cancer biology: The cancer swamp promotes the lethal cancer phenotype (2015) (71)
Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer (2017) (71)
Cellular harmonic information transfer through a tissue tensegrity-matrix system. (1991) (70)
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. (1997) (69)
Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. (2000) (69)
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. (2006) (69)
Early castration reduces prostatic carcinogenesis in transgenic mice. (1999) (68)
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. (2019) (68)
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. (2007) (68)
Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages (2018) (68)
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. (2019) (67)
Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. (1988) (67)
Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis (2008) (67)
Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. (2012) (66)
GREB1 is a novel androgen‐regulated gene required for prostate cancer growth (2006) (66)
Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. (2012) (66)
Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview (2000) (66)
Activating ESR 1 mutations in hormone-resistant metastatic breast cancer (2013) (66)
Tumor Necrosis Factor-α-induced Apoptosis in Prostate Cancer Cells through Inhibition of Nuclear Factor-κB by an IκBα “Super-Repressor” (2000) (65)
Definition of molecular determinants of prostate cancer cell bone extravasation. (2013) (65)
Homing of Cancer Cells to the Bone (2011) (64)
Role of transcriptional corepressor CtBP1 in prostate cancer progression. (2012) (64)
Cellular interactions in the tropism of prostate cancer to bone (2004) (64)
Drug Insight: use of docetaxel in prostate and urothelial cancers (2005) (62)
Detection and isolation of circulating tumor cells in urologic cancers: a review. (2004) (61)
The prostate cancer bone marrow niche: more than just 'fertile soil'. (2012) (61)
Disseminated tumor cells and dormancy in prostate cancer metastasis. (2016) (61)
Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. (2005) (61)
The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer (2016) (60)
Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. (1998) (60)
Synergy between anti‐CCL2 and docetaxel as determined by DW‐MRI in a metastatic bone cancer model (2009) (59)
Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone‐related protein (1999) (59)
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. (2011) (59)
A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells. (2016) (58)
CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac (2008) (57)
Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer (2007) (57)
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. (2015) (56)
RB Loss Promotes Prostate Cancer Metastasis. (2017) (56)
Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. (2009) (55)
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analy (2009) (55)
Amplification and overexpression of prosaposin in prostate cancer (2005) (54)
Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. (2012) (54)
Vitamin E, alpha- and gamma-tocopherol, and prostate cancer. (1999) (54)
Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium (2020) (54)
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. (2005) (53)
Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. (2015) (53)
In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. (2007) (52)
Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. (2004) (52)
Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. (2004) (52)
Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. (2017) (52)
New concepts in studying the control of normal and cancer growth of the prostate. (1987) (51)
The "emigration, migration, and immigration"of prostate cancer. (2005) (51)
Establishment and characterization of a new human prostatic cancer cell line: DuCaP. (2001) (51)
Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment (2018) (51)
Critical transitions in a game theoretic model of tumour metabolism (2014) (50)
Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer (2019) (50)
Oral etoposide in the treatment of hormone‐refractory prostate cancer (1994) (50)
Bone marrow macrophages support prostate cancer growth in bone (2015) (50)
CCL2, survivin and autophagy: New links with implications in human cancer (2008) (50)
PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT? (2016) (49)
Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single‐particle analysis platforms (2021) (49)
Circulating fibroblast‐like cells in men with metastatic prostate cancer (2013) (49)
The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells (2019) (49)
Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. (2017) (48)
SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework (2018) (48)
Development of the VCaP androgen-independent model of prostate cancer. (2006) (48)
Epidemiology of prostate cancer: molecular and environmental clues. (1996) (47)
CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. (2009) (47)
Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid? (2005) (46)
Niche Inheritance: A Cooperative Pathway to Enhance Cancer Cell Fitness Through Ecosystem Engineering (2014) (46)
Disrupting the Networks of Cancer (2012) (46)
Characterization of the subtypes of cell motility in ageing human skin fibroblasts (1990) (45)
Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. (2005) (45)
Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo (1993) (45)
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. (2020) (45)
Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and Progenitor Cells to Regulate Bone Phenotype (2012) (44)
New and emerging therapies for bone metastases in genitourinary cancers. (2013) (44)
Poly‐aneuploid cancer cells promote evolvability, generating lethal cancer (2020) (44)
Evidence of porcine and human endothelium activation by cancer‐associated carbohydrates expressed on glycoproteins and tumour cells (2004) (44)
Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. (1999) (44)
A sequence-based survey of the complex structural organization of tumor genomes (2008) (44)
Analysis of membrane-bound complement regulatory proteins in prostate cancer. (2005) (44)
Is dietary fat a risk factor for prostate cancer? (1993) (44)
In vivo real‐time imaging of TGF‐β‐induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer (2004) (43)
Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. (2003) (43)
Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer (2020) (42)
-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. (2008) (42)
Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells (2021) (41)
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. (1996) (41)
Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. (1993) (41)
Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. (2000) (41)
Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. (2019) (41)
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone‐refractory prostate carcinoma (2003) (41)
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions (2005) (40)
Preneoplastic alterations in nuclear morphology that accompany loss of tumor suppressor phenotype. (1991) (39)
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. (2021) (39)
Ecological paradigms to understand the dynamics of metastasis. (2016) (39)
Nanoparticle Induced Cell Magneto-Rotation: Monitoring Morphology, Stress and Drug Sensitivity of a Suspended Single Cancer Cell (2011) (39)
Identifying key questions in the ecology and evolution of cancer (2021) (38)
Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer (2016) (38)
The treatment of hormone refractory prostate cancer. (1996) (38)
PAR1‐mediated RhoA activation facilitates CCL2‐induced chemotaxis in PC‐3 cells (2007) (38)
Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer (2017) (37)
Paclitaxel in the treatment of hormone-refractory prostate cancer. (1999) (37)
Inhibitory Effects of Megakaryocytic Cells in Prostate Cancer Skeletal Metastasis (2010) (37)
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging (2018) (36)
Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake (2017) (36)
Phenotypic characterization of immortalized normal and primary tumor‐derived human prostate epithelial cell cultures (2000) (36)
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. (2021) (35)
Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer (2014) (35)
The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines (2004) (35)
Treatment of androgen‐independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study (2000) (35)
The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion (2017) (35)
CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. (2018) (35)
Loss of cell‐contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells (1995) (34)
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications (2018) (34)
Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. (2000) (34)
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies (2018) (34)
O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis (2016) (33)
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. (1993) (33)
Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion☆ (2020) (32)
Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium (2004) (32)
TAM macrophages promote growth and metastasis within the cancer ecosystem (2014) (32)
Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles (2011) (32)
Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. (2014) (31)
Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma (2003) (31)
A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. (2021) (31)
Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group (2018) (31)
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) * (2001) (31)
Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF‐α (2008) (30)
Inhibition of prostate cancer growth by estramustine and etoposide (1995) (30)
The effect of extracellular matrix interactions on morphologic transformation in vitro. (1991) (30)
Risk prediction tool for grade re‐classification in men with favourable‐risk prostate cancer on active surveillance (2017) (30)
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia (2017) (30)
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience (2019) (30)
Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. (2001) (29)
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy. (2020) (29)
The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. (2003) (29)
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. (1997) (29)
Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts (2009) (29)
AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer (2018) (29)
Unique Nuclear Matrix Protein Alterations in Head and Neck Squamous Cell Carcinomas: Intermediate Biomarker Candidates (1996) (28)
Pain management in patients with advanced prostate cancer. (1999) (28)
Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix. (1991) (28)
Inhibition of prostate cancer growth by estramustine and colchicine (1995) (28)
Cell motility as a chemotherapeutic target. (1991) (27)
Microvessel quantification as a measure of angiogenic activity in benign breast tissues lesions - a marker for precancerous disease. (1994) (27)
Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon Drug-Induced DNA Damage under Hypoxia (2014) (27)
Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer. (1999) (26)
Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology (2017) (26)
The Tumor Microenvironment at a Turning Point Knowledge Gained Over the Last Decade, and Challenges and Opportunities Ahead: A White Paper from the NCI TME Network. (2017) (26)
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells (2005) (26)
Supportive care in the patient with hormone refractory prostate cancer. (1997) (25)
Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories (2018) (25)
The utilization of nuclear matrix proteins for cancer diagnosis. (1996) (25)
A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer (2015) (25)
Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting (2019) (25)
Prostate cancer and parasitism of the bone hematopoietic stem cell niche. (2012) (25)
Endothelial integrin α3β1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane (2014) (24)
Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit. (2000) (24)
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms (2018) (24)
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies (2020) (24)
Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. (2017) (24)
Modeling signal transduction in normal and cancer cells using complex adaptive systems. (1997) (24)
A new concept in cancer care: The supportive care program (1999) (24)
Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. (2019) (24)
Characterization of TMPRSS 2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer (2008) (23)
AT‐101 (R‐(−)‐gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model (2010) (23)
Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer (2019) (23)
Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". (2000) (23)
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment (2018) (23)
Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility (1992) (23)
ROS-induced cell cycle arrest as a mechanism of resistance in polyaneuploid cancer cells (PACCs). (2021) (23)
3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification (2018) (23)
Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging (2018) (23)
Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas. (2018) (22)
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake (2020) (22)
3D Cell Nuclear Morphology: Microscopy Imaging Dataset And Voxel-Based Morphometry Classification Results (2017) (22)
Diagnosis and Treatment of Genitourinary Malignancies (2013) (22)
Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide (2015) (22)
Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC) (2007) (22)
Coupling of cell structure to cell metabolism and function (1994) (21)
Characterization of nuclear morphology and nuclear matrices in ageing human fibroblasts (1992) (21)
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials (2022) (21)
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) (2017) (21)
Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells (1992) (20)
An unstable nuclear matrix may contribute to genetic instability. (1994) (20)
AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort. (2016) (20)
Novel Structured Reporting Systems for Theranostic Radiotracers (2019) (20)
Expression mapping at 12p12‐13 in advanced prostate carcinoma (2004) (20)
Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan‐Coulter Translational Research Partnership Program (2010) (20)
Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration (2017) (20)
Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort (2010) (20)
Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts (2015) (19)
Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. (2011) (19)
Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey‐Holden Prostate Cancer Academy Meeting (2016) (19)
The effect of age on the response of the detrusor to intracellular mechanical stimulus: DNA replication and the cell actin matrix (1992) (19)
Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer (2018) (19)
Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem (2017) (18)
Results from the OSPREY trial: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY (2019) (18)
The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. (1997) (18)
Cancer cells homing to bone: the significance of chemotaxis and cell adhesion. (2004) (18)
4-Hydroxyphenylretinamide in the chemoprevention of cancer. (1995) (17)
Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting (2013) (17)
Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers (2020) (17)
Nuclear morphometry for prediction of metastatic potential in early squamous cell carcinoma of the floor of the mouth. (1992) (17)
Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer (2005) (17)
Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. (2009) (17)
Extracellular vesicle isolation from human renal cancer tissue (2020) (17)
Drug discovery in prostate cancer mouse models (2015) (16)
Somatostatin is an agonist and noncompetitive antagonist of gastrin in oxyntic cell function. (1981) (16)
Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. (2017) (16)
Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells (2017) (16)
Somatostatin in human pancreatic and gastric juice (1981) (16)
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer (2021) (15)
Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. (2017) (15)
A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18F-DCFPyL Positron Emission Tomography Imaging (2018) (15)
Biomanufacturing Seamless Tubular and Hollow Collagen Scaffolds with Unique Design Features and Biomechanical Properties (2017) (15)
A common set of nuclear matrix proteins in prostate cancer cells (1993) (15)
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting (2020) (15)
A multi-targeted approach to treating bone metastases (2014) (15)
Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer (2019) (15)
The Identification of Macrophage-enriched Glycoproteins Using Glycoproteomics * (2017) (14)
Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis. (2005) (14)
Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. (2005) (14)
A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial – mesenchymal cell reprogramming and cancer progression (2014) (14)
The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer. (2000) (14)
Microvessel quantification as a measure of angiogenic activity in benign breast-tissue lesions - a marker for precancerous disease. (1995) (14)
Epithelial–mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure (2015) (14)
Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting (2018) (14)
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide (2021) (14)
The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor (2015) (14)
Inhibition of prostate cancer growth by vinblastine and tamoxifen (1995) (14)
Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype (2017) (14)
Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer (2020) (14)
Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. (1999) (14)
Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. (1998) (13)
Etoposide in prostate cancer (2000) (13)
Beyond immune checkpoint blockade: New approaches to targeting host–tumor interactions in prostate cancer: Report from the 2014 Coffey–Holden prostate cancer Academy meeting (2015) (13)
The truth is out there: an overall perspective on androgen deprivation. (2003) (13)
A method to measure cellular adhesion utilizing a polymer micro-cantilever. (2013) (13)
Integrin alpha V beta 3 targeted dendrimer‐rapamycin conjugate reduces fibroblast‐mediated prostate tumor progression and metastasis (2018) (13)
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS) (2020) (13)
Murine Prostate Micro-dissection and Surgical Castration. (2016) (13)
A unifying model to explain the increased incidence and higher mortality of prostate cancer in black men. (1999) (13)
Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells (2018) (12)
Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis (2013) (12)
Role of dutasteride in pre‐clinical ETS fusion‐positive prostate cancer models (2012) (12)
The epidemiology of prostate cancer: clues for chemoprevention. (1994) (12)
Centralized Research Recruitment—Evolving a Local Clinical Research Recruitment Web Application to Better Meet User Needs (2011) (12)
PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis (2018) (12)
Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. (2007) (12)
The role of the nuclear matrix in cancer chemotherapy. (1999) (12)
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake (2020) (12)
Cancer Foraging Ecology: Diet Choice, Patch Use, and Habitat Selection of Cancer Cells (2018) (12)
Cancer as a Social Dysfunction—Why Cancer Research Needs New Thinking (2018) (12)
CD38 in Advanced Prostate Cancers (2021) (12)
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography–Guided Radiation Therapy for Oligometastatic Prostate Cancer (2019) (12)
The relationship of microvessel counts to tumor size, estrogen-receptor status, lymph-node metastasis, and disease-free survival in patients with stage-I and stage-ii breast-cancer. (1994) (11)
Recent advances in extracellular vesicle research for urological cancers: From technology to application. (2019) (11)
Novel molecular targets for prostate cancer therapy. (1999) (11)
Prostate Cancer Local Recurrence Detected With Both 18F-Fluciclovine and PSMA-targeted 18F-DCFPyL PET/CT. (2017) (11)
Stretch-mediated visceral smooth muscle growth in vitro. (1992) (11)
The Role of v3 in Prostate Cancer Progression 1 (2002) (11)
High-Throughput Simultaneous mRNA Profiling Using nCounter Technology Demonstrates That Extracellular Vesicles Contain Different mRNA Transcripts Than Their Parental Prostate Cancer Cells (2021) (11)
High KIFC1 expression is associated with poor prognosis in prostate cancer (2021) (11)
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. (2007) (11)
OC-0505: Interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer (2018) (10)
Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer (2020) (10)
Cancer Cell Foraging to Explain Bone-Specific Metastatic Progression. (2020) (10)
Aerobic glycolysis, motility, and cytoskeletal remodeling (2015) (10)
Integrated Multimodal Imaging of Dynamic Bone-Tumor Alterations Associated with Metastatic Prostate Cancer (2015) (10)
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. (1996) (10)
The Tissue Matrix and The Regulation of Gene Expression in Cancer Cells (1993) (9)
Development of doxorubicin resistant rat prostate cancer cell lines. (1997) (9)
The effect of castanospermine on the metastatic properties of prostate cancer cells. (1997) (9)
An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes. (2020) (9)
Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells (2018) (9)
Interplay between Cell Death and Cell Proliferation Reveals New Strategies for Cancer Therapy (2022) (9)
Explaining Aberrations of Cell Structure and Cell Signaling in Cancer Using Complex Adaptive Systems (1997) (9)
Evidence for lectin signaling to the nuclear matrix: Cellular interpretation of the glycocode (2000) (8)
Optimization of prostate cancer cell detection using multiplex tyramide signal amplification (2018) (8)
Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer (2019) (8)
The Hospice Supportive Care Program: a new "transitionless" model of palliative care for patients with incurable prostate cancer. (1996) (8)
The issues with tissues: the wide range of cell fate separation enables the evolution of multicellularity and cancer (2020) (8)
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. (2020) (8)
Cancer dormancy and criticality from a game theory perspective (2018) (8)
Preliminary Analysis of RTOG 9902: Increased Toxicity Observed with the Use of Adjuvant Chemotherapy (2005) (8)
Lipid droplet evolution gives insight into polyaneuploid cancer cell lipid droplet functions (2021) (8)
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics (2022) (8)
Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey–Holden Prostate Cancer Academy Meeting (2017) (8)
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma (2020) (7)
Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone‐refractory prostate carcinoma (2006) (7)
The 19th annual Prostate Cancer Foundation scientific retreat. (2013) (7)
Modified differential display technique that eliminates radioactivity and decreases screening time. (2000) (7)
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate. (1996) (7)
Antimetastatic drugs in prostate cancer. (2002) (7)
New treatment strategies for hormone refractory prostate cancer. (1995) (7)
Germ cell tumors: review of selected studies from 2002 (2003) (7)
Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression (2005) (7)
The combination of size‐based separation and selection‐free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer (2020) (7)
Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. (2013) (7)
Vitamins A and E: further clues for prostate cancer prevention. (1998) (7)
Chemotherapy in patients with prostate specific antigen–only disease after primary therapy for prostate carcinoma (2001) (7)
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey‐Holden Prostate Cancer Academy Meeting (2017) (6)
Signal transduction pathways and chromatin structure in cancer cells (2000) (6)
Differential carbohydrate expression in tumorigenic vs nontumorigenic prostate cell-lines. (1995) (6)
Characterization of tumor‐associated macrophages in prostate cancer transgenic mouse models (2021) (6)
Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy (2021) (6)
A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow (2016) (6)
Chemical transfection of dye‐conjugated microRNA precursors for microRNA functional analysis of M2 macrophages (2012) (6)
A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). (2018) (6)
Establishment of immortalized Copenhagen rat prostate endothelial cell lines. (1995) (6)
Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer (2021) (6)
Effect of organ site on nuclear matrix protein composition (1996) (6)
Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk-an unmeasured and masked mediator of potential significance? (2002) (6)
Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium (2011) (6)
The CTSA Mandate: Are We There Yet? (2010) (6)
Recent advances in chemotherapy for advanced prostate cancer (2000) (6)
Characterization of extracellular vesicles and artificial nanoparticles with four orthogonal single-particle analysis platforms (2020) (6)
Robots as models of evolving systems (2022) (5)
Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation (2017) (5)
Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer (2022) (5)
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer (2020) (5)
The Clinical and Translational Science Awards (CTSAs) Are Transforming the Way Academic Medical Institutions Approach Translational Research: The University of Michigan Experience (2011) (5)
The Chemokine CCL 2 Increases Prostate Tumor Growth and Bone Metastasis through Macrophage and Osteoclast Recruitment 1 (2014) (5)
Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi (2017) (5)
Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays-Reply. (2018) (5)
Erratum to: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression (2011) (5)
Preclinical studies of gossypol in prostate carcinoma. (1995) (5)
Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy. (2003) (5)
Commentary on the next two abstracts follows the second abstract. (2004) (5)
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy (2015) (5)
Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience. (1999) (5)
A model to study c-myc and v-H-ras induced prostate cancer progression in the Copenhagen rat. (1998) (5)
Polyaneuploid Cancer Cell Dormancy: Lessons From Evolutionary Phyla (2021) (5)
Role of biobanking in urology: a review (2016) (4)
Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications? (2019) (4)
Defining the clinical utility of PSMA‐targeted PET imaging of prostate cancer (2017) (4)
Optimized data-independent acquisition approach for proteomic analysis at single-cell level (2021) (4)
The isolation and characterization of epithelial cells from canine prostate. (1998) (4)
Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy (2021) (4)
Ten unanswered questions in cancer: "If this is true, what does it imply"? (2018) (4)
Role of the nuclear matrix in breast cancer. (1996) (4)
SIGNIFICANCE OF GLEASON PATTERN 4 AS AN INDEPENDENT PROGNOSTIC INDICATOR OF POSTOPERATIVE PSA FAILURE IN PROSTATIC ADENOCARCINOMA (1999) (4)
Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT (2017) (4)
PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework (2019) (4)
A surface tension magnetophoretic device for rare cell isolation and characterization (2017) (4)
Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP). (2018) (4)
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. (2012) (4)
The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. (1998) (4)
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy (2021) (4)
Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4 (2005) (4)
The role of liquid biopsies in prostate cancer management. (2021) (4)
Positive Feedback Loops Between Inflammatory, Bone and Cancer Cells During Metastatic Niche Construction. (2016) (4)
Bayesian Joint Hierarchical Model for Prediction of Latent Health States with Application to Active Surveillance of Prostate Cancer (2015) (4)
CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer (2020) (4)
Carboplatin-induced cell death in model prostate cancer systems. (1998) (4)
Establishment of an immortalized Copenhagen rat bone marrow endothelial cell line. (1996) (3)
Cell-morphodynamic phenotype classification with application to cancer metastasis using cell magnetorotation and machine-learning (2021) (3)
Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level (2020) (3)
A life history model of the ecological and evolutionary dynamics of polyaneuploid cancer cells (2022) (3)
Perspectives in Cancer Research Cancer as a Disease of DNA Organization and Dynamic Cell Structure1 (1989) (3)
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis (2022) (3)
A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma. (1998) (3)
Use of bisphosphonates in the treatment of prostate cancer. (2000) (3)
Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer (2022) (3)
Selection‐free method reveals phenotypic diversity among prostate cancer circulating tumour cells (2017) (3)
MP89-09 STROMAL DERIVED FACTOR-1 TREATMENT AUGMENTS NERVE REGENERATION VIA CXCR4 ACTIVATION OF NEUROTROPHIC FACTORS IN THE MAJOR PELVIC GANGLION IN A DOSE-DEPENDENT FASHION (2016) (3)
Dose escalation of oral vinorelbine in combination with estramustine in hormone‐refractory adenocarcinoma of the prostate (2006) (3)
Establishment of an immortalized Copenhagen rat prostate epithelial cell line. (1995) (3)
Modeling Cancer as A Complex Adaptive System: Genetic Instability and Evolution (2006) (3)
Understanding the tumor-immune microenvironment in prostate cancer (2021) (3)
Testicular cancer (2002) (3)
Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration–Resistant Prostate Cancer: Missing Parts in a Superb Study (2009) (3)
Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro (2021) (3)
Cell Motility and Structural Harmonics in Prostate Cancer (1991) (3)
PSA and PSA Doubling Time Predict Findings on 18F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer. (2020) (3)
DNA Organization in the Interphase Nucleus and Metaphase Chromosome (1990) (3)
Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer. (2017) (3)
Translational Research Program (2001) (3)
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation. (2019) (3)
Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. (2021) (3)
The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro. (1993) (2)
Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats. (1994) (2)
Stochastic models of Mendelian and reverse transcriptional inheritance in state-structured cancer populations (2022) (2)
A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219). (2013) (2)
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL (2022) (2)
Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). (2019) (2)
Tomlins et al. reply (2009) (2)
Stereotactic Ablative Radiation Therapy for the Treatment of Oligometastatic Prostate Cancer (2016) (2)
Abstract 3053: Stability and stemness of the hybrid epithelial-mesenchymal phenotype (2017) (2)
Measurement of PET Quantitative Bias In Vivo (2020) (2)
THERAPY FOR ADVANCED AND HORMONE REFRACTORY CANCER OF THE PROSTATE (2000) (2)
Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer (2021) (2)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. (2001) (2)
Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer (2018) (2)
Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy. (2016) (2)
Chapter 46 – Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy (2003) (2)
Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types (2020) (2)
1436: Comprehensive Assessment of TMPRSS2 and ETS Family Gene Aberrations in Clinically Localized Prostate Cancer (2007) (2)
GAMMA-TOCOPHEROL (NATURAL VITAMIN E) DEMONSTRATES GREATER INHIBITION OF GROWTH ON A HUMAN PROSTATE CANCER CELL LINE THAN ALPHA-TOCOPHEROL (SYNTHETIC VITAMIN E) (1999) (2)
It doesn’t always pay to be fit: success landscapes (2021) (2)
Abstract 4005: HDAC inhibitors regulate M2 tumor-associated macrophage function through histone acetylation (2017) (2)
New Discoveries in Prostate Cancer Biology and Treatment (2002) (2)
Role of Transcriptional Corepressor CtBP1 in Prostate (2012) (2)
Prostate cancer presenting as visual changes. (2006) (2)
Recurrent gene fusions in prostate cancer: ETV1 class of fusions (2007) (2)
The effect of hydrazine sulfate on prostate cancer growth. (1998) (2)
The Hematopoietic Stem Cell Niche and Bone Metastasis (2013) (2)
The Emergence of Polyploid Giant Cancer Cells as the Reservoir of Theraputic Resistance (2018) (2)
Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. (2019) (2)
Cells in the Polyaneuploid Cancer Cell (PACC) state have increased metastatic potential (2022) (2)
Game Theory Cancer Models of Cancer Cell-Stromal Cell Dynamics using Interacting Particle Systems (2020) (2)
A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. (2021) (2)
Forging the Association for Clinical and Translational Science (ACTS) (2012) (2)
Oligometastatic Prostate Cancer to the Navicular Bone: Case Report (2015) (2)
The Importance of Proposed Changes in the “Common Rule” for Clinical and Translational Researchers (2011) (2)
Prostate cancer research in the 21st century; report from the 2021 Coffey‐Holden prostate cancer academy meeting (2021) (2)
RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients (2022) (2)
Electroretinographic findings in subjects after administration of fenretinide (1995) (2)
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer (2022) (2)
Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification (2018) (2)
The Nuclear Matrix: an Organizing Structure for the Interphase Nucleus and Chromosome (1985) (2)
Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy (2020) (2)
Abstract 2365: Targeting M2-tumor associated macrophages (M2-TAMs) in prostate cancer (2015) (2)
Alterations in cellular gene expression without changes in nuclear matrix protein content (1994) (1)
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer (2013) (1)
Abstract 841: CCL2 and interleukin-6 regulate EMT-mediated chemo-resistance in prostate cancer (2012) (1)
Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head (2019) (1)
PSMA-Directed Biologically-Guided Radiation Therapy of Castration-Sensitive Oligometastatic Prostate Cancer Patients (2018) (1)
Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on 18F-DCFPyL PET/CT Scans (2022) (1)
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial (2023) (1)
Re: RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model. (2008) (1)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Translational Research Program. (2001) (1)
Metastasis Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer (2020) (1)
Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer (2021) (1)
Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia (2011) (1)
Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer (2020) (1)
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer (2015) (1)
Abstract IA21: Of niche construction and loss of homeostasis: New insights into the cancer diaspora (2015) (1)
Definitive therapy for men with newly-diagnosed oligometastatic prostate cancer: Initial surgical outcomes from a phase II study (2018) (1)
Abstract 953: Mechanistic rationale for inhibition of Poly(ADP-Ribose) Polymerase in ETS gene fusion positive prostate cancer (2011) (1)
Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis 1 (2016) (1)
New Paradigms in the Management of Hormone Refractory Disease (2000) (1)
Identification of gene copy number and whole-genome methylation changes associated with lethal metastatic castration-resistant prostate cancer (CRPC). (2011) (1)
Genitourinary cancer committee (2001) (1)
Abstract 4985: Notch1 as a key mediator in promoting advanced castration-resistant prostate cancer (2015) (1)
Abstract 365: Mobilizing prostate cancer cells from the endosteal niche by targeting the SDF-1/CXCR4 axis (2015) (1)
Tumor Necrosis Factor- a -induced Apoptosis in Prostate Cancer Cells through Inhibition of Nuclear Factor- k B by an I k B a “Super-Repressor” 1 (2000) (1)
Abstract 853: C1orf116, a gene with unknown function, is a novel driver of epithelial phenotype in epithelial-to-mesenchymal transition in human cancer (2017) (1)
Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern (2019) (1)
Chemoprevention of prostate cancer (1995) (1)
A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization (2020) (1)
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer  (2022) (1)
Abstract 2229: CD133+/CD44+ Cancer Stem Cells Represent a Disproportionately Large Fraction of Early Bone Disseminated Prostate Cancer Tumor Cells (2010) (1)
Abstract A37: Development of biologics targeting soluble ligands: Novel biomarker and PK-PD analyzes examining free and total ligand profile following treatment with carlumab (anti-CCL2 mAb). (2011) (1)
An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. (2017) (1)
Current chemotherapy regimens : What oncologists are using : Hormone refractory prostate cancer (1999) (1)
Simulating the Hallmarks of Cancer Robert G. Abbott (2006) (1)
Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation (2022) (1)
438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer (2021) (1)
PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL (2020) (1)
A Phase 2 Trial of Salvage Radiation and Concurrent Weekly Docetaxel After Rising PSA Post–Radical Prostatectomy (2014) (1)
InVivoReal-Time Imagingof TGF-b-Induced TranscriptionalActivationof theRANKLigandGene Promoter in Intraosseous ProstateCancer (2004) (1)
Parathyroid Hormone-related Protein as a Growth Regulator of Prostate Carcinoma 1 (1999) (1)
Abstract 1977: KIFC1 is a potential target to prevent treatment resistance in prostate cancer (2018) (1)
Letter to the Editor re: “Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake” (2019) (1)
Normal Organ Uptake Variability on PSMA-Targeted 18F-DCFPyL PET/CT (2016) (1)
Abstract 4582: Mannose receptor positive macrophage infiltrate correlates with prostate cancer onset and metastatic castration-resistant disease (2019) (1)
Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies (2018) (1)
Abstract 903: CXCR4 and CXCR7 play distinct and overlapping roles in prostate cancer dissemination to bone (2017) (1)
PD08-01 PREDICTION OF THE CANCER STATE TO INFORM A PERSONALIZED MANAGEMENT PROGRAM FOR PROSTATE CANCER (2016) (1)
targeted 18 F-DCFPyL PET / CT in the Preoperative Staging of Men with High-risk Prostate Cancer : Results of a Prospective Phase II Single-Center Study (2017) (1)
SYNTHESIS AND EVALUATION OF A RADIOIODINATED PHOSPHOLIPID ETHER ANALOG (NM-404) FOR DIAGNOSTIC IMAGING OF PROSTATE CANCER (2000) (1)
Immunomagnetic isolation of endothelial cells from normal rat prostate tissue. (1994) (1)
Current Chemotherapy Regimens: What Oncologists Are Using (1999) (1)
354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer (2020) (1)
Cancer as a Disease: Types of Tumors, Their Frequencies, and Their Progression (2008) (1)
A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells (2007) (1)
Development of a new instrument for measuring quality of life in patients undergoing therapy for prostate cancer (Meeting abstract). (1997) (1)
Reverse transcriptase- polymerase chain reaction (RT-PCR) to detect prostate cancer micrometastasis in the blood. (1996) (1)
Expression andActivationof a v b 3 Integrinsby SDF-1 / CXC 12 Increases theAggressiveness of ProstateCancerCells (2006) (1)
Medical oncology committee (2001) (1)
SABR Produces Systemic Adaptive Immune Responses in Castration-Sensitive Oligometastatic Prostate Cancer Patients (2018) (1)
Computer extracted nuclear features from Feulgen and H&E images to predict biochemical recurrence in prostate cancer patients following radical prostatectomy. (2016) (1)
Bone metastasis and cancer (2007) (1)
Possible Mechanism of CCL 2-induced Akt Activation in Prostate Cancer Cells (1)
Molecular radiosensitization of prostate cancer by modulating cell death pathways (2007) (1)
Abstract 3237: Assessment and targeting of M2-tumor associated macrophages (M2-TAMs) in prostate cancer (2016) (1)
The Prostate GREB 1 is aNovelAndrogen-RegulatedGene Required for ProstateCancerGrowth (2006) (0)
Capturing circulating tumor cells from a large blood volume: A pilot study using diagnostic leukapheresis (2019) (0)
Cover Image, Volume 120, Number 4, April 2019 (2019) (0)
Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score. (2022) (0)
MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY (2018) (0)
Smirnov, D. A. et al. Global gene expression profiling of circulating tumor cells. Cancer Res. 65, 4993-4997 (2005) (0)
A process for the inhibition of cancer metastasis by oral administration of soluble modified citrus pectin (1995) (0)
Book Reviews (1999) (0)
PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY) (2019) (0)
Abstract A001: Modeling cancer’s ecological and evolutionary dynamics (2022) (0)
Abstract 3803: Characterization of fluid biopsy using the HD-SCA platform to re-stratify intermediate-risk organ-confined prostate cancer patients (2017) (0)
Tumor and Stem Cell Biology Genetic Ablation of Metadherin Inhibits Autochthonous Prostate Cancer Progression and Metastasis (2014) (0)
Targeting Twist1-Hoxa9 to sensitize prostate cancer to PARP inhibition (2017) (0)
Interactions between neuromodulatory and hormonal control of oxyntic cell function (1981) (0)
Stochastic models of Mendelian and reverse transcriptional inheritance in state-structured cancer populations (2022) (0)
Abstract 123: Reactive oxygen species (ROS) as mediators of the cancer cell’s transition into the polyaneuploid cancer cell (PACC) state (2022) (0)
Abstract 983: Gas6/Axl mediation of prostate cancer cell dormancy requires cooperation with additional bone marrow niche components (2015) (0)
Why do tumor cells spread (2016) (0)
Abstract 1094: A role for olfactory-like chemosensory signaling in prostate cancer metastasis (2018) (0)
Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. (2003) (0)
Abstract 4060:In vitrohuman tumor-associated macrophage model implicates macrophage proliferation as a mechanism for maintaining tumor-associated macrophage populations (2018) (0)
Hormonal Manipulation of Prostate Cancer (2000) (0)
ETS rearrangements and prostate cancer initiation Reply (2008) (0)
Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. (2003) (0)
DETECTION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS FROM THE BONE MARROW IN LOCALIZED PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY: MP38‐15 (2017) (0)
MEASURING SEMINIFEROUS TUBULES DIAMETER USING HIGH FREQUENCY ULTRASOUND IN MURINE MODELS AND MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA AND OBSTRUCTIVE AZOOSPERMIA (2022) (0)
Abstract CT015: Safety and long-term efficacy of radioligand therapy using Lu-177 labeled PSMA ligands in metastatic prostate cancer: A single center experience over 5 years (2018) (0)
Abstract 1345: Interleukin-4 promotes cancer cell proliferation through the activation of the p38-mitotic activated protein kinase (MAPK) signaling pathway (2010) (0)
Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics. (2021) (0)
Phospho-proteomics reveals oncogenic phospho-tyrosine signaling networks in cancers lacking mutated or amplified tyrosine kinases (2013) (0)
Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer. (2016) (0)
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer (2022) (0)
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC (2022) (0)
Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype (2022) (0)
Abstract 1592: Identifying novel drivers of the epithelial-to-mesenchymal transition across multiple cancer types: from bioinformatics to the bench (2016) (0)
Optimized data-independent acquisition approach for proteomic analysis at single-cell level (2022) (0)
Computer extracted features on H&E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings. (2016) (0)
Cancer dormancy and criticality from a game theory perspective (2018) (0)
Abstract A028: Investigating the epigenetic landscape of chemotherapy-induced polyaneuploid prostate cancer cells (2022) (0)
Abstract 3017: The poly-aneuploid cancer cell state utilizes lipid droplets as a mechanism of survival (2022) (0)
Abstract 3369: Macrophages and their induced cytokines drive the epithelial to mesenchymal transition in prostate cancer cells (2011) (0)
Abstract 1383: Isolating circulating tumor cells from a large screening blood volume: A pilot study using diagnostic leukapheresis (2019) (0)
Understand the role of chemotherapeutic gradient in the emergence of polyploid giant cancer cells using mean field model (2019) (0)
NUCLEOLIN STAINING MAY AID IN THE IDENTIFICATION OF CIRCULATING PROSTATE CANCER CELLS: PD65‐04 (2017) (0)
Cancer Metastasis: Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics (2011) (0)
Abstract B015: Eco-evolutionary dynamics of poly-aneuploid cancer cells: A life history model (2022) (0)
Abstract 2939: Induction of apoptosis in prostate cancer cells by altering cell metabolism (2015) (0)
Targeting Efferocytic M2 Monocytes and Macrophages Offers Therapeutic Promise in Prostate Cancer Skeletal Metastasis (2015) (0)
Abstract SY39-02: Accessing evolutionary programs to enable therapeutic resistance (2022) (0)
Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer (2005) (0)
Exploration of mechanisms of drug resistance by polyaneuploid cancer cells in a microfluidic device and patient tissues (2022) (0)
Prognostic impact of circulating tumor cells in oligometastatic hormone-sensitive prostate cancer following metastasis-directed therapy. (2023) (0)
Reply by Authors. (2023) (0)
Abstract 6055: Polyaneuploid cancer cells are metabolically active and utilize lipid droplets to survive toxic stress (2023) (0)
Abstract IA27: The patient biosphere: Tumors live in people (2016) (0)
Abstract 2360: Targeting IL-4R alpha on tumor-associated macrophages as a therapeutic strategy for prostate cancer (2019) (0)
A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy (2016) (0)
Metastasis : The Interaction of Cancer and Its Host Environment (2017) (0)
Faculty Opinions recommendation of Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. (2013) (0)
Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET (2022) (0)
Abstract A50: Targeting CXCR4 and CXCR7 to mobilize and kill prostate tumor cells (2016) (0)
Abstract 4842: Stress-induced mitochondrial adaptations in the polyaneuploid cancer cell state (2023) (0)
Abstract 3909: Investigating the role of ANXA2R in metastatic prostate cancer (2017) (0)
Retraction: Characterization of Phosphoglycerate Kinase-1 Expression of Stromal Cells Derived from Tumor Microenvironment in Prostate Cancer Progression. (2022) (0)
Development of an automated and sensitive microfluidic device for circulating tumor cell (CTC) analysis and single cell capturing. (2016) (0)
Abstract IA017: The polyaneuploid cancer cell state as a mediator of therapeutic resistance (2022) (0)
A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. (0)
Abstract 2418: Microenvironment-on-chip: Development of a microfluidics-based tumor ecosystem (2016) (0)
Abstract 2546: Targeting MerTK-mediated efferocytosis in the prostate cancer TME (2022) (0)
regulation of innate immune responses and expression of Type I interferons, and ex vivo treatment of human and mouse immune cells with TAK-981 results in transcrip- tional upregulation of IFN-beta and Type I IFN receptor (2020) (0)
FGF and MAPK pathways are active in AR-null prostate cancer d Autocrine and paracrine FGF pathway activation can bypass AR dependence d Targeting the FGF and MAPK pathways can repress AR-null prostate cancer (0)
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer (0)
Are Poly-aneuploid Cancer Cells the Keystone Cure for Cancer? (2020) (0)
Abstract 5178: Homing of circulating prostate cancer cells to bone is regulated by alpha 1,3 fucosyltransferase 7 (2010) (0)
Effect of CCL2 on survival of breast cancer MDA-MB-231 cells via inhibition of apoptosis. (2009) (0)
Abstract 1572: Overexpression of Axl delays metastatic outgrowth of prostate cancer bone marrow disseminated tumor cells (2016) (0)
Toll-Like Receptor Agonist Induces IFN-gþIL-17þ Polyfunctional T Cells That Mediate Rejection of Murine Tumors (2012) (0)
In Situ Hybridization of Centromeric DNA as Visualized on the Nuclear Matrix by Laser Confocal Cytometry (1996) (0)
TheCurrent State of Preclinical ProstateCancerAnimalModels (2008) (0)
Abstract B026: Axl may support dormancy of disseminated tumor cells by inducing cell clustering and decreasing proliferation of metastatic prostate cancer cells (2018) (0)
Withdrawal: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer (2022) (0)
Abstract 125: The role of oxidative stress on the polyaneuploid cancer cell state in metastatic cancer (2022) (0)
Abstract 3774: Elevated cancer evolution dynamics: Emergence of polyploid cancer cells in response to multimodal therapy as an adaptive response on both individual and collective levels (2019) (0)
APhaseIITrialofEstramustineandEtoposide inHormoneRefractoryProstateCancer: ASouthwestOncologyGroupTrial(SWOG9407) (2001) (0)
Abstract 4975: Detection and characterization of circulating and disseminated tumor cells in patients with bladder and prostate cancer (2016) (0)
Obituary for Donald S. Coffey: Remembering a pioneer in the field of prostate cancer research. (1932-2017) (2018) (0)
Abstract 5100: Aerobic glycolysis is the primary metabolic pathway used for prostate cancer cell motility and invasion processes regardless of androgen sensitivity (2015) (0)
Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
Abstract B039: Multinucleation precedes the emergence of drug resistance in prostate cancer (2018) (0)
Alternatively activated monocytes/macropahges support prostate cancer skeletal metastasis (397.6) (2014) (0)
Nontraditional cancer treatments: Editorial (1999) (0)
Abstract B68: NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma (2020) (0)
Dosimetric Comparison of Biologically-Guided Radiotherapy and X-ray-Guided Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancer (2019) (0)
Prevention of Prostate Cancer (2003) (0)
Abstract 1139: Extracellular matrix components direct chromatin texture and nuclear morphological changes in epithelial-mesenchymal transition (2014) (0)
Abstract 53: Axl is sufficient but not necessary for disseminated prostate tumor cell dormancy (2018) (0)
3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification (2018) (0)
Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score. (2022) (0)
Detection of apoptosis in renal cell carcinoma. (2001) (0)
A multi-omics approach for kidney cancer biomarker discovery (2021) (0)
Abstract IA15: Targeting oligometastatic disease in prostate cancer (2018) (0)
Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer (2019) (0)
Abstract 4188: The role of microRNA-101 as a master tumor suppressor in cancer. (2013) (0)
Clinical Outcomes in Oligometastatic Prostate Cancer Following Definitive Radiation Therapy (2019) (0)
553 CUE-100 series Immuno-STATs from concept to the clinic: Leveraging protein engineering to stimulate and selectively deliver affinity-attenuated IL-2 to antigen-specific T cells (2020) (0)
Growth factor and cytokine antibody array analysis of human hormone refractory prostate cancer (HRPC) tumor specimens and sera (2005) (0)
Speaker Abstracts (2012) (0)
PD08-06 RISK PREDICTION TOOL FOR GRADE RECLASSIFICATION IN FAVORABLE-RISK MEN ON ACTIVE SURVEILLANCE (2016) (0)
Tumor specific exosome-based liquid biopsy biomarkers for kidney cancer (2021) (0)
Game Theory Cancer Models of Cancer Cell–Stromal Cell Dynamics Using Interacting Particle Systems (2020) (0)
Abstract 2205: KRTAP 2-3 is a novel potential biomarker of cells in the polyaneuploid cancer cell (PACC) state to predict cancer recurrence (2023) (0)
Treating advanced prostate cancer by disrupting host cell interactions in the tumor microenvironment (2008) (0)
Abstract 4942: Small molecule inhibition of CXCR4 mobilizes prostate disseminated tumor cells (DTCs) from the chemoprotective bone marrow niche, thereby sensitizing them to chemotherapy (2017) (0)
Abstract A35: Axl overexpression in a prostate cancer mouse model delays metastasis and may prolong dormancy of disseminated tumor cells (2016) (0)
Biological Differences Between Prostate Cancer Cells that Metastasize to Bone Versus Soft Tissue Sites (2004) (0)
Nuclear matrix protein composition of human lung carcinoma cell lines. (1996) (0)
Abstract B083: Disease marker-specific disseminated tumor cells in bone are rare at the time of radical prostatectomy (2018) (0)
Abstract 6493: Optimized methods for studies of extracellular vesicles in kidney cancer (2020) (0)
Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"? (2021) (0)
PD42-06 INTERMEDIATE-TERM OUTCOMES IN MEN WITH VERY HIGH RISK PROSTATE CANCER (2016) (0)
Abstract 3916: Disease-specific markers may be used for the identification of disseminated tumor cells in the bone marrow of patients with prostate cancer (2017) (0)
Correction: CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes (2021) (0)
Abstract 4890: Diffusion-weighted MRI provides an early assessment of treatment response in a murine model of metastatic prostate cancer to the bone (2011) (0)
Solid Tumors Target the HSC Niche to Establish Metastatic Footholds in the Marrow (2008) (0)
Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer. (2019) (0)
Abstract 371: A Pareto efficiency model to explain hybrid cellular behavior in tumor ecosystem (2014) (0)
Multiple Cancer Cell Population Dynamics in a Complex Ecology (2016) (0)
Abstract 342: Profiling mRNAs of parental prostate cancer cells with different phenotypes and their daughter extracellular vesicles using the NanoString low RNA input nCounter assay (2020) (0)
Abstract 4109: Unbiased detection of disseminated tumor cells in murine bone marrow (2016) (0)
Abstract B070: Epithelial-marker absent and disease-marker specific circulating and disseminated tumor cells are rarely detected in men with localized prostate cancer (2018) (0)
Rational use of chemotherapy. It is not just rat poison. (1999) (0)
Abstract PL06-04: Targeting the tumor ecosystem: Translating the molecular biology of chemokine interactions to the clinic. (2011) (0)
Cooperation among cancer cells: applying game theory to cancer (2018) (0)
The combination of size-based separation and selection-free technology provides higher CTC detection sensitivity than either method alone in patients with metastatic prostate cancer (2020) (0)
Nuclear morphology and functional characteristics that enable survival of cells in the polyaneuploid cancer cell state following cytotoxic chemotherapy (2022) (0)
Response to "Comment on 'A method to measure cellular adhesion utilizing a polymer micro-cantilever'" [Appl. Phys. Lett. 104, 236103 (2014)]. (2014) (0)
Extracellular Vesicle Uptake Assay via Confocal Microscope Imaging Analysis. (2022) (0)
The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells (2019) (0)
Dietary fiber and prostate cancer. (2001) (0)
MP05-02 CTC AND CTDNA ASSAYS REVEAL COMPLIMENTARY INFORMATION FOR METASTATIC UROTHELIAL CANCER PATIENTS (2019) (0)
Abstract 3918: Identification of disseminated prostate tumor cells in bone marrow during radical prostatectomy from patients with localized prostate cancer (2017) (0)
Abstract A017: Polyaneuploid Cancer Cells (PACCs) as metastasis-competent cells (2023) (0)
Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4. (2023) (0)
Compositions et methodes de detection et de traitement du cancer (2006) (0)
Abstract 1564: Reactive endosteum in prostate cancer bone metastases: role of tenascin-C in regulating cancer cell adhesion and proliferation (2016) (0)
18F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions. (2022) (0)
Serum PDGF Decreases during Combined Radiation and Androgen Deprivation Therapy for Prostate Cancer (2009) (0)
CLASSIFICATION OF TUMORS, THEIR FREQUENCY AND PROGRESSION (2019) (0)
186 Bioinformatics and gene discovery in prostate cancer (2009) (0)
MP39-02 NEW EXOSOMAL PROTEIN AND MRNA BIOMARKERS FOR RENAL CANCER (2021) (0)
Abstract 1358: Tumor-derived extracellular vesicles as kidney cancer biomarkers (2019) (0)
Abstract A030: Systematic optimization of multiplex immunofluorescence of bone marrow eliminates false positives in the detection of disseminated tumor cells (2018) (0)
Erratum: Tumor necrosis factor-α-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-κB by an IκBα "super-repressor," (Clinical Cancer Research (2002) 6 (1969-1977)) (2002) (0)
Abstract B11: O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis (2020) (0)
Bladder Cancer: Epidemiology & Evaluation IIIPD57-02 CHARACTERIZATION OF UROTHELIAL CANCER CIRCULATING TUMOR CELLS WITH A NOVEL SELECTION-FREE METHOD (2017) (0)
990 SPANXB2 EXPRESSION INCREASES PROSTATE CANCER AGGRESSIVITY: A NEW VIEW OF STROMAL-EPITHELIAL CELL INTERACTION (2013) (0)
Abstract 1394: CD44 isoform expression illuminates multiple CSC subpopulations in PC3 (2015) (0)
Abstract 1686: Leiomyosarcoma poly-aneuploid cancer cells form in response to chemotherapy and contribute to chemoresistance (2023) (0)
Prostate Cancer Chemotherapy (2001) (0)
Abstract B022: The polyaneuploid transition as a hedge against failures in resistance acquisition (2022) (0)
Abstract 4945: Axl-hi DTCs in the bone marrow of a genetically engineered mouse model of prostate cancer exhibit decreased proliferation (2017) (0)
Nuclear morphometry for predicting cervical metastatic potential in laryngeal squamous-cell carcinoma. (1995) (0)
Nuclear morphology predicts cell survival to cisplatin chemotherapy (2023) (0)
A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP). (2017) (0)
An Enhancing Renal Mass in Metastatic Prostate Cancer. (2023) (0)
Metastatic prostate cancer cell lines expressing PSA for allogeneic cancer vaccine development (2004) (0)
Seminar article Development of the VCaP androgen-independent model of prostate cancer (2006) (0)
CCL2 INCREASES IN VIVO TUMOR GROWTH OF HUMAN PROSTATE CANCER PC-3 TUMOR XENOGRAFT (2009) (0)
Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging (2023) (0)
Abstract 1078: An immunosuppressive signature in bone marrow as a potential biomarker for recurrence of metastatic prostate cancer after prostatectomy (2019) (0)
Abstract 2884: Tumor-driven eutrophication of the tumor ecosystem selects for cancer cell clones that overcome evolutionary inertia leading to increased metastatic capacity (2015) (0)
IDENTIFICATION OF DISSEMINATED TUMOR CELLS IN THE BONE MARROW WITH DISEASE‐SPECIFIC MARKERS AT RADICAL PROSTATECTOMY: MP20‐20 (2017) (0)
Abstract 166: MicroRNA profiling analysis identify new signature of tumor-promoting M2-type macrophages (2011) (0)
720 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies (2021) (0)
Correction: The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer (2017) (0)
Abstract A72: Prostate cancer spheroid formation in a 384 hanging drop array plate. (2011) (0)
Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis (2017) (0)
PD51-03 DIGITAL PATHOLOGY OF CIRCULATING TUMOR CELLS WITH MORPHOLOGIC ANALYSIS IS FEASIBLE IN LOCALIZED BLADDER CANCER (2020) (0)
Abstract 2268: Tenascin C as an effector of prostate cancer derived bone metastasis (2015) (0)
636 A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers (2022) (0)
Issue Information (2018) (0)
Perspectives in Oncology: a new article type for Medical Oncology (2020) (0)
Modes of Failure Following Metastasis Directed Therapy in Patients with Oligometastatic Hormone Sensitive Prostate Cancer: A Multi-institutional Analysis (2020) (0)
Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. (2017) (0)
Comment on: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. Authors' reply (1998) (0)
UROLOGICAL ONCOLOGY: PROSTATE CANCER Autoantibody Signatures in Prostate Cancer (2006) (0)
A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization (2020) (0)
Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer. (2023) (0)
Abstract B2-24: OVOL: A brake on EMT, driver of MET and expander of the hybrid E/M phenotype (2015) (0)
Modeling cancer’s ecological and evolutionary dynamics (2023) (0)
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial (2023) (0)
Abstract 4556: Targeting the TAM receptors on prostate cancer tumor-associated macrophages (2019) (0)
Epithelial^MesenchymalTransitioninProstateCanceris Associated With Quantifiable Changesin Nuclear Structure (2014) (0)
Abstract B06: Targeting M2-Tumor Associated Macrophages (M2-TAMs) in prostate cancer (2017) (0)
MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL (2021) (0)
Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells (2018) (0)
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting (2022) (0)
Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates (2011) (0)
Abstract 5192: Detection of disseminated prostate cancer cells in bone marrow using tyramide signal amplification (2018) (0)
Prostate Cancer Chemotherapy: Closing Out a Century and Opening a New One (2000) (0)
Abstract 3156: C1orf116, an uncharacterized gene with unknown function, restricts movement capacity of would-be metastatic cells through modulation of tight junctions (2018) (0)
Abstract 1919: Profiling of cancer cell lines demonstrates a dynamic relationship between epithelial, mesenchymal and cancer stem states (2014) (0)
Abstract 712: Antitumor activity of SPINK1 monoclonal antibody in a subset ofSPINK1positiveETS-negative prostate cancer (2010) (0)
Dormant cancer cells: programmed quiescence, senescence, or both? (2023) (0)
Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer (2012) (0)
Abstract B055: Optimized human monocyte-derived macrophage cultures accurately reflect macrophage immunomodulatory function (2018) (0)
Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification (2018) (0)
Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer. (2022) (0)
Reply by Authors. (2021) (0)
Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer (2022) (0)
Hormone refractory prostate cancer surgical craft: Transvaginal sling procedure with bone anchor fixation: Preface (1999) (0)
MP39-13 DEVELOPMENT OF A NOVEL METHOD FOR DETECTING RENAL CELL CARCINOMA CIRCULATING TUMOR CELLS (2015) (0)
Bone Metastatic Tumors Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for (2011) (0)
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression (2023) (0)
Hormonal manipulation of prostate cancer with sequential androgen blockade. (2010) (0)
Abstract A037: C1orf116, a gene of unknown function, promotes tight junctions and epithelial cell phenotype in prostate cancer (2018) (0)
Abstract 4631: Multiplex IHC assay to explore regional heterogeneity of FAP and inflammatory cell density in localized prostatic adenocarcinoma (2023) (0)
Abstract C02: Ecological movement paradigms to understand the dynamics of metastasis (2016) (0)
Abstract 1405: Macrophages induce a transcriptional program that triggers a stable epithelial to mesenchymal transition in prostate cancer cells (2012) (0)
Biologic activity of prosomatostatin (SS-28) and cyclic somatostatin (SS-14) on oxyntic cell function (1981) (0)
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment (2019) (0)
Induced Expression of Androgen Receptor in Androgen Independent Prostate Cancer Cells Using an I kappa B alpha "Super Repressor" (2002) (0)
Poster ViewingChanges in Radiotherapeutic Management of Prostate Cancer Following PSMA-based 18F-DCFPyL PET Imaging: A Snapshot of Prospective Trials at a Single Institution (2017) (0)
Abstract 5365: Profiling circulating tumor cell RNA from a large blood screening volume: A pilot study using diagnostic leukapheresis followed by the NanoString low RNA input nCounter assay (2020) (0)
Angiogenesis , Metastasis , and the Cellular Microenvironment Hypoxia Stabilizes GAS 6 / Axl Signaling inMetastatic Prostate Cancer (2012) (0)
PD15-12 BLADDER CANCER CIRCULATING TUMOR CELL CONCENTRATION FLUCTUATES IN THE ABSENCE OF SYSTEMIC THERAPY OR SURGERY (2018) (0)
Abstract B018: Targeting Notch4 and HIF2α signaling reduces the ability of cells to survive chemotherapy by undergoing the polyaneuploid transition (2022) (0)
Molecular Mechanisms of Prostate Cancer Progression After Castration (2014) (0)
Abstract 3704: Targeting M2-tumor associated macrophages (M2-TAMs) using enriched glycoproteins in lethal prostate cancer (2017) (0)
Tumor and Stem Cell Biology De fi nition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation (2013) (0)
A multi-targeted approach to treating bone metastases (2014) (0)
1443 PROSTATE CANCER INTERACTION WITH MATURE AND PROGENITOR BONE MARROW DERIVED CELLS OF THE MONOCYTIC LINEAGE (2010) (0)
Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS). (2022) (0)
WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. (2023) (0)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. (2001) (0)
CHARACTERIZATION OF UROTHELIAL CANCER CIRCULATING TUMOR CELLS WITH A NOVEL SELECTION‐FREE METHOD: PD57‐02 (2017) (0)
Impact of the cancer endocycle on cell survival after therapy (2022) (0)
Abstract 1592: Bladder cancer circulating tumor cell concentration fluctuates in the absence of systemic therapy or surgery (2018) (0)
HypoxiaStabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer (2012) (0)
MP69-12 PREDICTORS OF SURGICAL CURE IN MEN WITH VERY HIGH RISK PROSTATE CANCER (2016) (0)
Origin and evolution of animal multicellularity in the light of phylogenomics and cancer genetics (2022) (0)
Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer. (2020) (0)
Effects of water deprivation on water balance in DOCA hypertensive pigs (1981) (0)
MP09-11 TRENDS IN SURGICAL MANAGEMENT OF HIGH-RISK PROSTATE CANCER: EVIDENCE OF AN EVOLVING TREATMENT PARADIGM (2016) (0)
The 19 th Annual Prostate Cancer Foundation Scienti fi c Retreat (2013) (0)
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS) (2020) (0)
Celastrol, an active ingredient in Chinese herbal medicine, radiosensitizes human prostate cancer via modulating NF-kB-signaling pathway (2008) (0)
Abstract 1023: Release of cancer cells from the prostate tumor microenvironment to promote neoantigen exposure and enhance anti-tumor immune response (2018) (0)
Abstract 5988: A non-canonical CDK9 complex mediates endocycling in polyaneuploid cancer cell (PACC) state (2023) (0)
Common nuclear matrix proteins in human and rat prostate cancer cells (1993) (0)
Abstract 4597: Bladder cancer patients experience circulating tumor cell number surge during intramedullary nailing procedures intended for treating pathological fractures (2019) (0)
Molecular and Cellular Pathobiology Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer (2012) (0)
Role of WNT Pathway Mutations within Oligometastatic Castration-Sensitive Prostate Cancer (2022) (0)
681 A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer (2022) (0)
Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration (2017) (0)
Clonal culture and chemodrug assay of heterogeneous cells (PC3 prostate carcinoma cells) using microfluidic single cell array chips (2009) (0)
Abstract 140: Polyaneuploid prostate cancer cells induced via chemotherapy have predominantly large, single nuclei (2022) (0)
Lack of repeatability of radiomic features derived from PET scans: Results from a 18F‐DCFPyL test–retest cohort (2023) (0)

This paper list is powered by the following services:

Other Resources About Kenneth J. Pienta

en.wikipedia.org

What Schools Are Affiliated With Kenneth J. Pienta?

Kenneth J. Pienta is affiliated with the following schools:

Kenneth J. Pienta's Academic­Influence.com Rankings

Why Is Kenneth J. Pienta Influential?

Kenneth J. Pienta's Published Works

Published Works

Other Resources About Kenneth J. Pienta

What Schools Are Affiliated With Kenneth J. Pienta?

Image Attributions

Kenneth J. Pienta's AcademicInfluence.com Rankings